By upregulating these transcription factors in IPF fibroblasts we may be able to restore RXFP1 expression and thus responsiveness to relaxin-based therapeutics in fibrotic fibroblasts. The gene discussed is RXFP1; the disease is idiopathic pulmonary fibrosis.